Navigation Links
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator

VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM). The data was disclosed as part of the preclinical characterization of the development candidate EVP-0962.

EVP-0962 is a proprietary small molecule that belongs to a new generation of potential Alzheimer drugs known as gamma-secretase modulators (GSMs). As a gamma-secretase modulator, EVP-0962 selectively inhibits the production of the toxic AB42 peptide without affecting the total amount of AB. As EVP-0962 does not affect other gamma secretase substrates required for normal function, such as Notch, it is predicted to slow the progression of Alzheimer's disease by reducing the disease-associated toxic AB42 species and to display an intrinsically superior safety profile compared to gamma secretase inhibitors (GSIs).

EVP-0962 selectively reduces the production of AB42 in multiple cell lines and in the brains of normal mice and rats after a single dose. It significantly reduces the production of AB42 in the brains of transgenic mice after two months of daily oral administration. In the same transgenic Alzheimer's disease model, mice developed deficits in the hippocampal memory task known as contextual fear conditioning. Chronic dosing with EVP-0962 reverses these deficits back to normal (wild type) levels. EVP-0962 also displays an excellent safety profile in a 14-day rat toxicology study, confirming suitability for clinical development.

"We are very excited about these findings since they represent to us the first demonstration with a bona fide GSM of functional improvement in an Alzheimer's disease model with concomitant lowering of AB42," said Kees Been, president & CEO of EnVivo. "We have also described the acute AB42 lowering effects of EVP-0962 in brains of non-transgenic as well as transgenic rodents. The fact that EVP-0962 also improves the cognitive deficits is very encouraging and confirms that EVP-0962 is an ideal molecule to test the AB-hypothesis in our upcoming human clinical trials."

Based on the success of these experiments, EnVivo has now entered preclinical development with EVP-0962 and expects to begin clinical trials in 2010.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
4. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
5. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
6. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
7. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
10. OncoGenex Pharmaceuticals Added to Russell Indexes
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
(Date:10/12/2015)... Rochelle, Virginia (PRWEB) , ... October 12, 2015 ... ... LLC announced today that Dr. Srini Srinivasan, has joined the firm as a ... expertise and professional stature enable them to bring extraordinary value to the company's ...
(Date:10/10/2015)... -- Le 8 octobre, l,honorable Doris O. Matsui ... Congrès sa déclaration de soutien à la troisième ... plasma (IPAW), qui se tiendra du 11 au ... Protein Therapeutics Association (PPTA) et ses sociétés ... Sensibiliser l,opinion publique mondiale autour du don de ...
(Date:10/9/2015)... Pa. and ROCKVILLE, Md. ... Inc. ("ITI"), a privately-held biotechnology company developing next ... announced that it has entered into an exclusive ... LAMP-vax products for the treatment or prevention of ... execution of the agreement, Immunomic Therapeutics will receive ...
(Date:10/9/2015)... San Francisco, CA (PRWEB) , ... October 09, 2015 , ... ... with a study that aims to better understand the relationship between weight management and ... more frequently and more accurately from participants using an iPhone app. , The uBiome ...
Breaking Biology Technology:
(Date:10/1/2015)...  Biometrics includes diverse set of technologies used ... as fingerprints, eye retinas, facial patterns, voice patterns, ... has been constantly increasing in India ... addition to the most prominent popular method of ... of biometric authentication are rapidly gaining traction in ...
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):